Asset Purchase Agreement (Details) - USD ($)		3 Months Ended
	Dec. 17, 2014	Jun. 30, 2015
Asset Purchase Agreement
Capital contribution - cash paid to acquire certain intellectual property and research and development		$ 750,000
Research and development expense		$ 10,608,000
Services Agreement | RVT-101 | GSK
Asset Purchase Agreement
Deferred payment payable upon certain conditions being met	$ 5,000,000
One-time payment upon achieving certain sales target	85,000,000
Threshold global net sales amount for payment of post closing amount	$ 1,200,000,000
Royalty on annual net sales (as a percent)	12.50%
Research and development expense	$ 5,000,000
Services Agreement | RVT-101 | GSK | Deferred payment payable
Asset Purchase Agreement
Research and development expense	5,000,000
Services Agreement | RVT-101 | GSK | United States
Asset Purchase Agreement
Deferred payment payable upon certain conditions being met	35,000,000
Services Agreement | RVT-101 | GSK | European Union
Asset Purchase Agreement
Deferred payment payable upon certain conditions being met	25,000,000
Services Agreement | RVT-101 | GSK | Japan
Asset Purchase Agreement
Deferred payment payable upon certain conditions being met	10,000,000
RSL | Services Agreement | RVT-101 | GSK
Asset Purchase Agreement
Capital contribution - cash paid to acquire certain intellectual property and research and development	$ 5,000,000